Proactive Research analyst Emma Ulker says () is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services.
She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries.
Click here to read Emma Ulker's latest update Open Orphan: Scaling Up, Leveraging Valuable Assets
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE
